{
    "nct_id": "NCT05029960",
    "official_title": "Tolerability and Activity of Brivaracetam (BRV) in Patients With Diffuse Gliomas",
    "inclusion_criteria": "* Age â‰¥ 18 years with pathologic diagnosis of a supratentorial diffuse astrocytic or oligodendroglial tumor\n* Patients must be able to provide informed consent\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* A pre-existing seizure disorder or epilepsy syndrome prior to tumor diagnosis\n* Active maintenance therapy with an antiepileptic seizure drug (AED) prior to diagnosis of tumor\n* Patients who have experienced an epileptic seizure as the presenting symptom of their brain tumor\n* Predicted life expectancy of less than 6 months from the time of screening\n* Pregnancy\n* Patients with clinically significant hepatic disease (elevated aminotransferases [bilirubin, alkaline phosphatase] > 3 times upper limit normal)\n* Patients with stage 4 or greater renal disease (GFR <30 mL/min/1.73 m2)\n* Patients who are unable to swallow a tablet\n* Patients with active suicidal ideation or a history of suicide attempt or other serious psychiatric disorder having required hospitalization within the previous 2 years.",
    "miscellaneous_criteria": ""
}